Market Research Report
LUM001- Emerging Insight and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||974750|
|Published||Pre-Order||Content info||60 Pages
Delivery time: 10 business days
|LUM001- Emerging Insight and Market Forecast - 2030|
|Published: Pre-Order||Content info: 60 Pages||
"LUM001- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Alagille syndrome in 7 Major Markets. A detailed picture of the LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. By reducing serum bile acids with a once-daily oral tablet, LUM001 may offer a novel therapeutic approach for alleviating the severe itching and progressive liver damage associated with many cholestatic liver diseases. LUM001 has received Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development in four rare cholestatic liver diseases including primary biliary cirrhosis; progressive familial intrahepatic cholestasis; Alagille syndrome; and primary sclerosing cholangitis.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
LUM001 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of LUM001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of LUM001 covering trial interventions, trial conditions, trial status, start and completion dates.